{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-042652","form_type":"8-K","ticker":"ANGO","cik":"0001275187","company_name":"ANGIODYNAMICS INC","filed_at":"2024-10-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.947457+00:00","generated_at":"2026-05-30T21:12:41.913606+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"AngioDynamics Q1 FY2025 net sales $67.5M (+1.1% pro forma); GAAP EPS -$0.31, adj. EPS -$0.11","bullets":["Med Tech segment sales $28.0M (+8.7% YoY) driven by Auryon at $13.7M (+24.9%) and AlphaVac at $2.2M (+21.1%).","Med Device segment sales $39.5M (-3.6% YoY); U.S. Med Device grew 2.1%.","GAAP net loss $12.8M ($0.31 loss/share); adjusted net loss $4.4M ($0.11 loss/share).","Submitted NanoKnife PRESERVE study to FDA for 510(k) prostate tissue indication; received CE Mark for Auryon in Europe.","FY2025 guidance reaffirmed: net sales $282-288M, adj. EBITDA loss $2.5M-$0, adj. EPS loss $0.38-$0.42."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-042652","json":"https://secwatch.observer/filing/0001140361-24-042652.json","markdown":"https://secwatch.observer/filing/0001140361-24-042652.md","text":"https://secwatch.observer/filing/0001140361-24-042652.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1275187/000114036124042652/0001140361-24-042652-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1275187/000114036124042652/ef20036580_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T21:12:41.913606+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}